Englande v. SMITHKLINE

206 F. Supp. 2d 815, 2002 U.S. Dist. LEXIS 16372, 2002 WL 1370004
CourtDistrict Court, E.D. Louisiana
DecidedFebruary 8, 2002
DocketCIV.A. 01-3743
StatusPublished
Cited by2 cases

This text of 206 F. Supp. 2d 815 (Englande v. SMITHKLINE) is published on Counsel Stack Legal Research, covering District Court, E.D. Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Englande v. SMITHKLINE, 206 F. Supp. 2d 815, 2002 U.S. Dist. LEXIS 16372, 2002 WL 1370004 (E.D. La. 2002).

Opinion

ORDER AND REASONS

FELDMAN, District Judge.

Before the Court is the plaintiffs Motion to Remand or alternatively, Motion to Stay. For the reasons that follow, the motion to remand is GRANTED.

Background

Andrew Englande claims that he suffered injuries during his participation in a clinical trial of the drug. Lotrafiban. On August 2, 2001, Englande filed a medical malpractice complaint with the Louisiana Patients’ Compensation Fund against Dr. Bruce Iteld, Daphne Dureau, RN, and the Louisiana Heart Center, and requested a panel review of his claims. The next day, Englande sued Dr. Iteld, Dureau, Bernstein and Associates, L.L.C. d/b/a Louisiana Heart Center, and the manufacturer of the drug, SmithKline Beecham Corporation d/b/a GlaxoSmithKline (“SB”), in Louisiana state court. The petition alleges that Iteld, Dureau, and Bernstein & Associates are Louisiana citizens and states a malpractice claim against them. SB is a Pennsylvania corporation with its principal place of business in that state. Englande directed that service be withheld on all defendants until late November, 2001. On December 6, 2001, Englande dismissed the health care providers without prejudice, pending the completion of the medical review process, and reserving his right to proceed against SB. On December 14, 2001, SB removed the case to this Court based on diversity jurisdiction. Englande now moves to remand.

Law and Application

Pursuant to 28 U.S.C. § 1441(a), a party may remove an action pending in state court to a federal court if the action is one over which the federal court possesses subject matter jurisdiction. The removing party bears the burden of showing that federal jurisdiction exists and thus that removal was proper. De Aguilar v. Boeing Co., 47 F.3d 1404, 1408 (5th Cir.1995); Allen v. R & H Oil & Gas Co., 63 F.3d 1326, 1335 (5th Cir.1995); Jernigan v. Ashland Oil Inc., 989 F.2d 812, 815 (5th Cir.1993) (per curiam); Willy v. Coastal Corp., 855 F.2d 1160, 1164 (5th Cir.1988). To determine whether jurisdiction is present for removal, the Court considers the claims in the state court petition as they existed at the time of removal. Cavallini v. State Farm Mut. Auto Ins. Co., 44 F.3d 256, 264 (5th Cir.1995). Any ambiguities are construed against removal, as the removal statute should be strictly construed in favor of remand. Acuna v. Brown & Root, Inc., 200 F.3d 335, 339 (5th Cir.2000); York v. Horizon Fed. Sav. & Loan Ass’n, 712 F.Supp. 85, 87 (E.D.La.1989). In this case, the defendant asserts federal jurisdiction on the basis of diversity, which *817 requires complete diversity of citizenship and an amount in controversy in excess of $75,000, exclusive of interest and costs. 28 U.S.C. § 1382.

If the initial pleading is not removable because of lack of diversity, but subsequent pleadings create complete diversity, a defendant may, in some circumstances, remove the case to federal court. See 28 U.S.C. 1446(b). Furthermore, under the “voluntary-involuntary” rule, if a resident defendant is dismissed from the ease by the voluntary act of the plaintiff, leaving only diverse parties, then the case may be removed. But if a resident defendant is dismissed as a result of either the defendant’s or the court’s acting against the wishes of the plaintiff, the case cannot be removed. See Weems v. Louis Dreyfus Corp., 380 F.2d 545 (5th Cir.1967); see also Phillips v. Unijax, Inc., 625 F.2d 54 (5th Cir.1980). Furthermore, it is only where the plaintiff, by his voluntary act, “definitely and clearly indicates his intention to abandon or discontinue the action against a non-diverse defendant that the action becomes removable.” McLin v. Surgitex, Inc., 1992 WL 67801 (E.D.La.)(Wicker, J.)(citing Aydell v. Sterns, 677 F.Supp. 877 (M.D.La.1988)). Non-diverse parties may remain in federal court, however, if the non-diverse defendants were fraudulently joined. See Doe v. Cutter Biological, 774 F.Supp. 1001 (E.D.La.1991)(Feldman, J.). The removing defendant bears the burden of proving that non-diverse defendants have been fraudulently joined to defeat diversity. Cavallini v. State Farm Mut. Auto Ins. Co., 44 F.3d 256, 259 (5th Cir.1995). A party is considered fraudulently joined when the plaintiff has not or cannot state a claim for relief against that individual or entity under the applicable substantive law or does not intend to secure a judgment against that defendant. Erdey v. American Honda Co., Inc., 96 F.R.D. 593, 595 (M.D.La.1983)(Parker, J.).

Louisiana law requires that medical malpractice claims must be administratively considered by a medical review panel before one files a lawsuit. La.R.S. 40:1299.47 B(l)(a)(i) mandates that “[n]o action against a health care provider ... may be commenced in any court before the claimant’s proposed complaint has been presented to a medical review panel....” If a plaintiff sues first, and then submits his claim to a medical review panel, his case may be dismissed as premature, which is a dismissal without prejudice. See Cutter Biological, 774 F.Supp. at 1004.

In the present case, Englande filed suit before his claims were presented to a medical review panel. • See Brister v. Southwest Louisiana Hosp. Ass’n, 624 So.2d 970 (La.App. 3 Cir.1993) (holding that medical malpractice suit was premature where suit was filed one day after request was made for panel review); see also Jarrell v. American Medical Intern., Inc., 552 So.2d 756 (La.App. 1 Cir.1989), writ denied 556 So.2d 1282 (stating that plaintiff was required to convene a medical review panel before filing suit); see also Johnson v. Scimed, Inc., 92 F.Supp.2d 587 (W.D.La.2000) (stating that Louisiana law requires the completion of the medical review process before a plaintiff may sue). Thus, his was a premature filing under Louisiana law.

District courts have applied the voluntary-involuntary rule in a number of cases involving premature Louisiana medical malpractice claims. The plaintiffs in McLin v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
206 F. Supp. 2d 815, 2002 U.S. Dist. LEXIS 16372, 2002 WL 1370004, Counsel Stack Legal Research, https://law.counselstack.com/opinion/englande-v-smithkline-laed-2002.